These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20626228)

  • 21. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
    Dudley-Brown S; Nag A; Cullinan C; Ayers M; Hass S; Panjabi S
    Gastroenterol Nurs; 2009; 32(5):327-39. PubMed ID: 19820441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab (Tysabri) for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2005 Feb; 47(1202):13-5. PubMed ID: 15711498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F; Cohen M; Lebrun C
    Rev Neurol (Paris); 2010 Apr; 166(4):412-8. PubMed ID: 19846185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natalizumab for multiple sclerosis?
    Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
    Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
    Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ; Muniyappa K
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Multiple sclerosis: between wish and reality].
    Kümpfel T; Hohlfeld R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():83-5. PubMed ID: 15968879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.
    Cree BA; Stuart WH; Tornatore CS; Jeffery DR; Pace AL; Cha CH
    Arch Neurol; 2011 Apr; 68(4):464-8. PubMed ID: 21482925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
    Oliver B; Fernández O; Orpez T; Alvarenga MP; Pinto-Medel MJ; Guerrero M; León A; López-Madrona JC; Maldonado-Sánchez R; García-León JA; Luque G; Fernández V; Leyva L
    Mult Scler; 2011 Mar; 17(3):368-71. PubMed ID: 21177326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S;
    J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.